Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Dispelling the myths of dealmaking trends

This article was originally published in Scrip

Executive Summary

The release of Q1 deals data from MedTRACK, showing a 13% fall in pharma/biotech product and technology deal volume compared with last year and a 9% drop on the last quarter of 2010 (see Figure 1), prompted many to question why dealmaking activity is going down when, seemingly, the need for it has never been greater. This natural reaction underlines the importance of understanding, and dispelling, some of the myths and assumptions around deals trending.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register